VERIGRAFT starts 2024 off with a major progress in our TECVI-1 first-in-man trial: Half of the patients have been treated.
1/11/2024
Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the Company has successfully regenerated plants from single cells in a wheat cultivar. This is a major breakthrough for Cibus as well as for the industry.
1/9/2024
ADC Therapeutics SA (NYSE: ADCT) today provided business updates. “During 2023, we took a number of decisive actions to help position the Company for success in 2024 and beyond. We prioritized our pipeline, strengthened our organization and implemented a disciplined capital allocation model to generate cost efficiencies,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. “We believe we are starting to see signs of the commercial turnaround. We are also encouraged to see positive initial signals in the LOTIS-7 trial of ZYNLONTA in combination with bispecifics as well as early signs of antitumor activity in the Phase 1b trial of ADCT-601. We now expect our cash runway to extend into the fourth quarter of 2025 and believe we are on a path to unlock the substantial value in the Company.”
1/4/2024
Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses gene edited plant traits to seed companies for royalties, today announced that it has entered into a Collaboration Agreement with Interoc, a company with more than 25 years in Latin America, focused on the research and development of solutions for agriculture. Starting with Cibus’ rice herbicide tolerance traits, Cibus has agreed to partner with Interoc to provide traits for Interoc’s elite rice seed genetics.
1/4/2024
ADC Therapeutics SA (NYSE: ADCT) today announced initial results from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab demonstrated a high response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL). The data from the single-institution study conducted at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine were reported during an oral presentation yesterday at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition by the study’s lead investigator, Juan Pablo Alderuccio, MD, associate professor of medicine and hematologist at Sylvester.
12/12/2023
Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, acknowledges the European Union notification to World Trade Organization (WTO) members on the European Commission proposal for regulation of plants obtained from New Genomic Techniques (NGTs) on 31st October. The notification is intended to ensure any potential trade barriers are avoided and invites comments from WTO members by the year end.
12/1/2023
Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today a collaboration to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-‘749) by entering into a funding agreement of up to $125 million to offset program costs. Olanzapine LAI (TEV-‘749) is a once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine that is currently in Phase 3 for the treatment of schizophrenia and has the potential to be the first long-acting olanzapine with a favorable safety profile.
11/14/2023
Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche’s Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
10/19/2023
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced several CAPLYTA data presentations at the 2023 Psych Congress held September 6 - 10, 2023 in Nashville.
9/11/2023
Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s Adstiladrin® (nadofaragene firadenovec-vncg) for up to US $500 million comprised of an upfront payment of US $300 million and a US $200 million milestone payment. The milestone payment is contingent on certain manufacturing goals that are expected to be achieved in 2025 for the FDA-approved intravesical gene therapy that Ferring will make available next month through an early experience program for the treatment of adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
8/24/2023
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced several CAPLYTA data presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held in Miami, May 30 - June 2, 2023.
5/31/2023
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced positive topline results from Study 403 evaluating lumateperone 42mg as monotherapy in the treatment of major depressive episodes in patients with major depressive disorder with mixed features and in patients with bipolar depression with mixed features.
3/28/2023
Royalty Pharma plc (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences industry, and PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT for up to $500 million with $100 million in cash up front and up to $400 million in additional payments contingent on the achievement of certain regulatory and commercial milestones.
3/23/2023
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. The merger will create a new industry-leading company that combines the two pioneers in agriculture-based gene editing and establishes one of the world's most sophisticated facilities for trait development and next-generation plant breeding.
1/17/2023
Annals of Internal Medicine. Published online on November 8, 2022, 10.7326/M22-1438.
11/8/2022
ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan.
7/8/2022
Enterin brings a unique steroid close to market with help from Pfizer. Pfizer is the world’s largest drug company, and its visibility has only grown in the past 2 years after its launch of both a vaccine and a therapy for COVID-19. Together, those products will generate about $54 billion in sales for Pfizer this year.
7/4/2022
LiquiGlide®, the inventors of a breakthrough technology that is revolutionizing products, packaging, processes, and patient experiences by eliminating the friction between solids and liquids, Aon plc (NYSE: AON), a leading global professional services firm, and Atlas Credit Partners, an asset management firm focused on value-oriented credit investments, today announced the completion of an intellectual-property based financing deal that provides LiquiGlide with $35 million to expand its commercial activities and continue to develop its platform for new applications.
4/22/2022
Today VERIGRAFT announces that the company has successfully reached the safety assessment milestone in the first patient of the TECVI-1 clinical trial in which the safety of P-TEV for the treatment of CVI is investigated.
3/2/2022
Intelinair and Airbus announced today a multi-year collaboration agreement that will provide high-resolution, Airbus satellite imagery as an input to Intelinair’s artificial intelligence (AI) powered crop analytics AGMRI® platform to deliver a complete view of every acre, every field from planting to harvest.
2/23/2022
